Abstract: The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.
Type:
Grant
Filed:
May 26, 2015
Date of Patent:
July 17, 2018
Assignee:
EGIS GYOGYSZERGYAR ZRT
Inventors:
Ede Laszlo Marvanyos, Attila Virag, Tamas Gregor, Balazs Volk, Maria Tothne Lauritz, Laszlo Pongo, Balazs Peregi, Gyula Lukacs, Zoltan Varga, Andras Dancso